A Phase I/II Trial of Sorafenib and CCI-779 in Combination With Recurrent Glioblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Temsirolimus (Primary) ; Sorafenib
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2018 Status changed from active, no longer recruiting to completed.
- 03 Jan 2018 Results published in the Cancer
- 31 May 2013 Interim results (n=44) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.